Currently Enrolling Case Studies

Breast Cancer (3rd Line) #BRE001:
For Study Participants with HER2+ Metastatic Breast Cancer who have Received two Prior Treatments. NCT02492711

Breast Cancer #BRE003:
For Study Participants with Metastatic Breast Cancer who have Stable Brain Metastases and Have Been Previously Treated with Anthracycline, A Taxane, and Capecitabine. NCT02915744

Chronic Myelomonocytic Leukemia (CMML)
Study Drug with IV verses oral drug in subjects with Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndromes (MDS)
Study Drug with IV verses oral drug in subjects with Myelodysplastic Syndromes (MDS). NCT03306264

Head & Neck #HEN001:
For Study Participants with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. NCT02952586

Lung #LUN001:
EGFR-mutated tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) participants. NCT02819518
Lung #LUN002:
Subjects with advanced or metastatic NSCLC who have received no more than 1 line of therapy,
Who are check point inhibitor/naïve, who are not eligible for or cannot tolerate therapy with a specific targeted inhibitor of a driver. NCT02646748

Lymphoma (2nd Line +) #LYM003:
For Study Participants with Relapsed Indolent B-Cell Non-Hodgkin’s Lymphoma (iNHL). NCT02367040

Lymphoma #LYM004:
A Phase 1, open-label, dose-escalation study in Adult patients with advanced malignancies.

Lymphoma #LYM005:
A Multi-center, open label, dose escalation, Phase 1/11b study to evaluate the safety and efficacy of Channel inhibitor in patients with relapsed or refractory Lymphomas. NCT03119647

Multiple Myeloma MEL002:
A Phase 2/3 (Adaptive Design) study for Adult patients with Unrespectable Stage 3 or Stage 4 Malignant Melanoma. NCT03301636

Ovarian OVA004:
A Phase 1b/2 Study for Patients with relapsed & refactoring Ovarian Cancer. NCT02880371

Pancreatic #PAN001
A Phase 1b/2 Study of Patients with Pancreatic Cancer. NCT02880371

Renal (3rd Line) #REN003:
For Study Participants with Advanced or Metastatic Renal Cell Carcinoma. NCT03163667

REN004 (Adjuvant)
A Phase 111, randomized, double–blind trial in the Adjuvant treatment of Renal Cell Carcinoma Post Nephrectomy. NCT03142334

Solid Tumors/Advanced #P1-STA001
For Study Participants with Advanced Solid Tumors. NCT02880371

Solid Tumors/Advanced #P1-STA002:
For Study Participants with BRAF V600-Mutant, Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors. NCT02952586

Solid Tumors/Advanced #P1-STA004:
A first in Human Phase 1 Trial to Determine the Safety and the Pharmacokinetic Profile in Patient with Advance solid Tumors. NCT03416816

Urothelial #URO001:
Platform Study Exploring the Safety, tolerability, Effects on the Tumor Microenvironment of Combinations in Advanced Solid Tumors. NCT02646748